1-2 of 2
Ulrich von Grünhagen, MD
Close
Sort by
Journal Articles

Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

Thoralf Lange, MD, Rainer Krahl, PhD, Ulrich von Grünhagen, MD, Haifa Kathrin Al-Ali, Schwarzer Andreas, MD, Kathleen Jentsch-Ulrich, MD, Claudia Spohn, MD, Volker Lakner, MD, Michael Assmann, MD, Christian Junghanss, MD, Markus Pfirrmann, Arthur Gil, PhD, Rüdiger Hehlmann, MD, Michael W. Deininger, MD PhD, Dietger Niederwieser, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1615.
https://doi.org/10.1182/blood.V130.Suppl_1.1615.1615
Published: 2017
Journal Articles

Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study

Mathias J. Rummel, MD, Georg Maschmeyer, MD, Arnold Ganser, Andrea Heider, PhD, Ulrich von Grünhagen, MD PhD, Christoph Losem, Gerhard Heil, MD, Manfred Welslau, Christina Balser, MD, Ulrich Kaiser, MD, Eckhart Weidmann, Heinz Dürk, MD, Hans Peter Böck, Martina Beate Stauch, MD, Jürgen Barth, Wolfgang Blau, MD, Alexander Burchardt, MD, Frank Kauff, PhD, Axel Hinke, PhD, Wolfram Brugger, MD
Journal: Blood
Blood (2014) 124 (21): 4407.
https://doi.org/10.1182/blood.V124.21.4407.4407
Published: 2014